Source: International Congress 2019 – Pulmonary hypertension with lung diseases and experimental pulmonary hypertension
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
E. Schiavi (Parma, Italy), S. Cantoni (Parma, Italy), G. Volpi (Parma, Italy), M. Cont (Parma, Italy), F. Pastore (Parma, Italy), S. Cavalli (Parma, Italy), F. Dardi (Bologna, Italy), G. Villetti (Parma, Italy), F. Facchinetti (Parma, Italy). Macitentan modulates pulmonary mRNA levels of gremlin 1 in a rat model of pulmonary arterial hypertension. 1418

Member's Comments

No comment yet.

Related content which might interest you: Interleukin-13-dependent regulation of endothelin-1 expression in pulmonary arterial hypertension Source: Annual Congress 2007 - Pulmonary hypertension Year: 2007 A novel piperidine attenuates pulmonary arterial hypertension via regulating BMP2 and PTGS2 levels Source: International Congress 2018 – Pathobiology of pulmonary hypertension Year: 2018 Shroom expression is attenuated in hypoxia-induced pulmonary hypertension Source: Eur Respir J 2006; 28: Suppl. 50, 147s Year: 2006 TrkB expression is altered in hypoxia-induced pulmonary hypertension Source: Eur Respir J 2007; 30: Suppl. 51, 606s Year: 2007 Regulation of connexins by hypoxia in rat pulmonary vascular cells in an in vitro model of pulmonary hypertension Source: International Congress 2017 – Experimental PH Year: 2017 IL-6 receptor overexpression in pulmonary arterial smooth muscle cells in idiopathic pulmonary hypertension Source: International Congress 2015 – Pulmonary hypertension: novel insights into the biology of the disease Year: 2015 Expression of the serotonin 1b receptor in experimental pulmonary hypertension Source: Eur Respir J 2003; 22: 408-412 Year: 2003 Decreased expression of the TGF-beta type I receptor ALK1 in pulmonary arterial hypertension Source: Annual Congress 2007 - Cellular and molecular aspects of pulmonary hypertension Year: 2007 Shroom expression is attenuated in pulmonary arterial hypertension Source: Eur Respir J 2008; 32: 871-880 Year: 2008 Gene expression alterations in mice lacking the VIP gene are conducive to pulmonary arterial hypertension and pulmonary vascular remodeling Source: Annual Congress 2007 - Cellular and molecular aspects of pulmonary hypertension Year: 2007 ACE2 activation improves pulmonary endothelial function and attenuates monocrotaline-induced pulmonary hypertension Source: Annual Congress 2011 - Treatment of human pulmonary hypertension Year: 2011 Dexamethasone reverses monocrotaline-induced pulmonary arterial hypertension in rats Source: Eur Respir J 2011; 37: 813-822 Year: 2011 Expression of fetal genes in pulmonary arterial hypertension Source: Annual Congress 2005 - Pulmonary hypertension and fibrosis: novel mechanisms Year: 2005 Pulmonary arterial hypertension (PAH) in mice lacking the vasoactive intestinal polypeptide (VIP) gene: morphometric evidence for vascular remodeling Source: Annual Congress 2006 - Signalisation in the pulmonary vasculature: new pathways and wrong signals Year: 2006 Late Breaking Abstract - NGF induces pulmonary arterial hyperreactivity through increased connexin-43 expression: potential role in pulmonary hypertension Source: International Congress 2018 – Molecular mechanisms and treatment of pulmonary hypertension Year: 2018 Early atorvastatin administration suppresses the oxygen-activating ability of rat neutrophils during monocrotalinin-induced pulmonary arterial hypertension (PAH). Source: Virtual Congress 2020 – Experimental approaches to pulmonary hypertension Year: 2020 Survivin inhibition as a potential target for pulmonary arterial hypertension Source: International Congress 2019 – Pulmonary hypertension: novelties from the bench Year: 2019 Endothelin receptor expression in idiopathic pulmonary arterial hypertension: effect of bosentan and epoprostenol treatment Source: Eur Respir J 2011; 38: 851-860 Year: 2011 Microarray analysis of pulmonary gene expression in mice lacking the vasoactive intestinal peptide (VIP) gene: confirmation of a role in asthma and pulmonary arterial hypertension (PAH) Source: Annual Congress 2006 - Cellular mechanisms of airway disease Year: 2006 Optimization of tissue targeting properties of macitentan, a new dual endothelin receptor antagonist, improves its efficacy in a rat model of pulmonary fibrosis associated with pulmonary arterial hypertension Source: Annual Congress 2011 - Treatment of human pulmonary hypertension Year: 2011